Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2001-12-12
pubmed:abstractText
Fibrinolytic activity has been reported to be decreased in atherosclerosis. Recently, annexin II was identified as a coreceptor on endothelial cells for plasminogen and tissue plasminogen activator. In this study, we examined whether recombinant annexin II (rAN II) protein can modulate fibrinolytic activity on vascular endothelium in vitro and in vivo. The effect of rAN II on human umbilical vein endothelial cells (HUVECs) was measured. Addition of a fluorescent plasmin substrate revealed that HUVECs treated with rAN II exhibited significantly more plasmin generation than those treated with BSA. Moreover, rAN II treatment of HUVECs restored plasmin generation impaired by plasminogen activator inhibitor-1 or homocysteine pretreatment. In a rat carotid artery thrombus model, the patency of thrombosed carotid arteries was significantly enhanced by rAN II injection, in contrast to BSA injection, without systemic blood coagulation dysregulation. We found that rAN II enhanced plasmin generation on vascular endothelium in vitro and reduced thrombus formation in vivo, and concluded that enhancement of endothelial fibrinolytic activity by annexin II could modulate the hypercoagulable state of atherosclerosis. Further study of rAN II in vitro and in vivo may lead to the establishment of novel therapeutic approaches to thrombogenic vascular disease.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1524-4571
pubmed:author
pubmed:issnType
Electronic
pubmed:day
7
pubmed:volume
89
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1240-5
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:11739291-Animals, pubmed-meshheading:11739291-Annexin A2, pubmed-meshheading:11739291-Bleeding Time, pubmed-meshheading:11739291-Blood Coagulation, pubmed-meshheading:11739291-Blotting, Western, pubmed-meshheading:11739291-Carotid Arteries, pubmed-meshheading:11739291-Carotid Artery Thrombosis, pubmed-meshheading:11739291-Cells, Cultured, pubmed-meshheading:11739291-Disease Models, Animal, pubmed-meshheading:11739291-Endothelium, Vascular, pubmed-meshheading:11739291-Fibrinolysin, pubmed-meshheading:11739291-Fibrinolysis, pubmed-meshheading:11739291-Homocysteine, pubmed-meshheading:11739291-Humans, pubmed-meshheading:11739291-Immunohistochemistry, pubmed-meshheading:11739291-Male, pubmed-meshheading:11739291-Plasminogen Activator Inhibitor 1, pubmed-meshheading:11739291-Rats, pubmed-meshheading:11739291-Rats, Sprague-Dawley, pubmed-meshheading:11739291-Recombinant Proteins
pubmed:year
2001
pubmed:articleTitle
Recombinant annexin II modulates impaired fibrinolytic activity in vitro and in rat carotid artery.
pubmed:affiliation
Department of Medicine, School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
pubmed:publicationType
Journal Article, In Vitro, Research Support, Non-U.S. Gov't